MedAdvisor Limited

CHIA:MDR Stock Report

Market Cap: AU$162.6m

MedAdvisor Valuation

Is MDR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MDR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MDR (A$0.3) is trading below our estimate of fair value (A$0.77)

Significantly Below Fair Value: MDR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDR?

Key metric: As MDR is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MDR. This is calculated by dividing MDR's market cap by their current revenue.
What is MDR's PS Ratio?
PS Ratio1.3x
SalesAU$122.11m
Market CapAU$162.64m

Price to Sales Ratio vs Peers

How does MDR's PS Ratio compare to its peers?

The above table shows the PS ratio for MDR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average17.7x
CGS Cogstate
2.6x10.9%AU$171.8m
ONE Oneview Healthcare
13.2x25.9%AU$209.0m
BMT Beamtree Holdings
2.5x21.9%AU$69.5m
4DX 4DMedical
52.5x66.8%AU$197.1m
MDR MedAdvisor
1.3x13.4%AU$162.6m

Price-To-Sales vs Peers: MDR is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (17.7x).

Price to Sales Ratio vs Industry

How does MDR's PS Ratio compare vs other companies in the AU Healthcare Services Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x17.8%
MDR MedAdvisor
 1.3x13.4%US$105.00m
DOC Doctor Care Anywhere Group
0.3x6.3%US$14.92m
IME ImExHS
0.7x20.5%US$11.93m
MDR 1.3xIndustry Avg. 2.9xNo. of Companies7PS0816243240+
8 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x20.8%
MDR MedAdvisor
 1.3x69.1%US$105.00m
No more companies

Price-To-Sales vs Industry: MDR is good value based on its Price-To-Sales Ratio (1.3x) compared to the Global Healthcare Services industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is MDR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: MDR is expensive based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MDR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.29
AU$0.55
+85.3%
13.0%AU$0.62AU$0.45n/a3
Nov ’25AU$0.25
AU$0.55
+118.7%
13.0%AU$0.62AU$0.45n/a3
Oct ’25AU$0.44
AU$0.57
+30.3%
6.4%AU$0.62AU$0.53n/a3
Sep ’25AU$0.45
AU$0.57
+28.8%
6.4%AU$0.62AU$0.53n/a3
Aug ’25AU$0.52
AU$0.56
+8.1%
14.2%AU$0.64AU$0.45n/a3
Jul ’25AU$0.50
AU$0.51
+1.3%
10.7%AU$0.58AU$0.45n/a3
Jun ’25AU$0.44
AU$0.45
+2.3%
7.3%AU$0.49AU$0.41n/a3
May ’25AU$0.29
AU$0.42
+46.0%
8.0%AU$0.47AU$0.39n/a3
Apr ’25AU$0.28
AU$0.40
+46.7%
6.5%AU$0.44AU$0.38n/a3
Mar ’25AU$0.30
AU$0.40
+33.3%
6.5%AU$0.44AU$0.38n/a3
Feb ’25AU$0.29
AU$0.39
+34.5%
6.3%AU$0.42AU$0.36n/a3
Jan ’25AU$0.21
AU$0.40
+84.5%
4.3%AU$0.42AU$0.38n/a3
Dec ’24AU$0.23
AU$0.40
+72.5%
4.3%AU$0.42AU$0.38n/a3
Nov ’24AU$0.21
AU$0.40
+84.5%
4.3%AU$0.42AU$0.38AU$0.253
Oct ’24AU$0.22
AU$0.40
+80.3%
4.3%AU$0.42AU$0.38AU$0.443
Sep ’24AU$0.24
AU$0.40
+61.9%
4.3%AU$0.42AU$0.38AU$0.453
Aug ’24AU$0.23
AU$0.40
+71.7%
1.3%AU$0.40AU$0.39AU$0.522
Jul ’24AU$0.24
AU$0.40
+66.7%
2.5%AU$0.41AU$0.39AU$0.502

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Cogstate

AU$171.8m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.99

7D

4.7%

1Y

-31.4%

SDI

AU$127.8m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.08

7D

5.4%

1Y

29.5%

Doctor Care Anywhere Group

AU$23.1m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.063

7D

-10.0%

1Y

26.0%